Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021

(2021) Tom T. Shimabukuro et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection

(2021) Nina Le Bert et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

(2021) Merryn Voysey et al.   LANCET

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

(2021) Denis Y Logunov et al.   LANCET

First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021

(2021) Julianne Gee et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

(2021) Robert H Shaw et al.   LANCET

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

(2021) Andreas Greinacher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice

(2021) Alexandra J. Spencer et al.   Nature Communications

Validation of a commercially available SARS-CoV-2 serological immunoassay

(2020) B. Meyer et al.   CLINICAL MICROBIOLOGY AND INFECTION

Sex-Based Vaccine Response in the Context of COVID-19

(2020) Patricia Robin McCartney   JOGNN-JOURNAL OF OBSTETRIC GYNECOLOGIC AND NEONATAL NURSING

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

(2020) Pedro M Folegatti et al.   LANCET

Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults

(2020) Mark J. Mulligan et al.   NATURE

A thermostable, closed SARS-CoV-2 spike protein trimer

(2020) Xiaoli Xiong et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

(2020) Lisa A. Jackson et al.   NEW ENGLAND JOURNAL OF MEDICINE

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

(2020) Ugur Sahin et al.   NATURE

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

(2020) Evan J. Anderson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

(2020) Maheshi N Ramasamy et al.   LANCET

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

(2020) Jordan R. Barrett et al.   NATURE MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prime-boost vaccine strategy against viral infections: Mechanisms and benefits

(2016) Kimia Kardani et al.   VACCINE